psoriasis

47 days ago

Another question for the Skinbiotherapeutics AGM: Superdrug, the rush to discount and the lack of reviews

Unable to sleep last night I checked out the Superdrug website and to have a look at the Skinbiotherapeutics (SBTX) acne and psoriasis products.
Acne sure is a crowded field, Superdrug sells 376 products including the one from Skins. 

---

979 days ago

SkinBioTherapeutics – SkinBiotix additional formal studies, a short-term delay but enhanced outlook: STRONG BUY

SkinBioTherapeutics (SBTX) has announced on its AxisBiotix-Ps (psoriasis) product that it has commenced sales in Spain aided by the launch of a regional website and on its skin care active ingredient SkinBiotix that partner, cosmetics business of FTSE-100 Croda (CRDA), Sederma has noted ‘exciting’ additional benefits which means delays in monetisation. Is that good news or bad?

---

1436 days ago

SkinBioTherapeutics – “Business update”, expect shares to respond positively on further updates soon: BUY!

SkinBioTherapeutics (SBTX) has published a Business update” announcement including that it has now progressed to the second phase of its AxisBiotix-Ps food supplement for psoriasis product commercialisation strategy and that the SkinBiotix active ingredient project with Sederma is on track. Sounds good!

---

1547 days ago

SkinBioTherapeutics – launch of first commercial product, high margin profit potential from this cracking share tip

SkinBioTherapeutics (SBTX) has announced it has commercially launched its probiotic food supplement to help alleviate the symptoms associated with psoriasis, AxisBiotix-Ps.

---

1695 days ago

SkinBioTherapeutics – positive study results suggest this could be a six bagger from here!

SkinBioTherapeutics (SBTX) has announced the results of the AxisBiotix-PsT consumer study of patients suffering from psoriasis and it says that it will now be seeking regulatory approval for the product as a food supplement in parallel in the UK, US and Europe… targeting a commercial launch of theAxisBiotix-Ps™ product in Q4 2021”.  Do the maths! This is going to be massive.

---

1722 days ago

SkinBioTherapeutics – new research programme adds to the vast potential but its looming Winclove results which are the key

Noting that “there is now an extensive growing body of research demonstrating direct links between the microbiome and the immune system, and consequently skin health”, SkinBioTherapeutics (SBTX) announced, a couple of weeks ago, initiation of a research programme with the University of Manchester. This is good news but not the elephant in the room!

---